Trial Profile

A Phase 2b Randomized, Open-Label Active Controlled Study Evaluating the Safety and Efficacy of Oral VH4524184 Coadministered With Emtricitabine and Tenofovir Alafenamide in Treatment Naive Viremic Persons With HIV-1 (INNOVATE Study)

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VH 4524184 (Primary) ; Dolutegravir/lamivudine; Emtricitabine/tenofovir alafenamide
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms INNOVATE Study
Sponsors ViiV Healthcare

22 Dec 2025 Planned End Date changed from 19 Mar 2029 to 1 Nov 2028.
22 Dec 2025 Planned primary completion date changed from 11 Jun 2027 to 20 May 2027.
22 Dec 2025 Planned initiation date changed from 28 Nov 2025 to 6 Feb 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com